Interventional Oncology Ablation

Global Interventional Oncology Ablation Market to Reach US$884.0 Million by 2030

The global market for Interventional Oncology Ablation estimated at US$563.2 Million in the year 2024, is expected to reach US$884.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$469.5 Million by the end of the analysis period. Growth in the Microwave Ablation segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$153.4 Million While China is Forecast to Grow at 12.4% CAGR

The Interventional Oncology Ablation market in the U.S. is estimated at US$153.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$190.8 Million by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Interventional Oncology Ablation Market – Key Trends & Drivers Summarized

Why Is Interventional Oncology Ablation Emerging as a Critical Modality in Cancer Treatment?

Interventional oncology ablation has become an essential therapeutic approach in the minimally invasive treatment of solid tumors, offering a localized, image-guided alternative to traditional surgical resection and systemic therapies. This technique involves the use of energy-based devices—such as radiofrequency (RF), microwave, cryoablation, and irreversible electroporation—to destroy cancerous tissues without the need for open surgery. It is most frequently used for patients with liver, lung, kidney, bone, and soft tissue tumors, particularly when surgery is not feasible due to tumor location, size, or patient comorbidities.

The precision of interventional oncology ablation, guided by modalities such as ultrasound, CT, or MRI, enables targeted treatment while sparing healthy surrounding tissue. It is increasingly used in combination with systemic therapies like chemotherapy and immunotherapy, or as a bridge to transplantation or surgery. The demand for less invasive, outpatient-based cancer treatments with faster recovery, fewer complications, and cost savings is making tumor ablation a preferred option in early-stage or oligometastatic disease management.

What Technologies Are Advancing the Capabilities of Tumor Ablation in Interventional Oncology?

The interventional oncology ablation field is undergoing significant technological advancement, particularly in ablation device design, image-guidance systems, and thermal control algorithms. Microwave ablation systems, known for their ability to achieve higher temperatures and faster ablation times than RF ablation, are increasingly favored in treating large and deep-seated tumors. Cryoablation systems provide enhanced visualization during treatment and are often used where precision margins are critical, such as in renal or prostate tumors.

Advanced image-guidance technologies—including real-time 3D navigation, contrast-enhanced ultrasound, and MR thermometry—are improving ablation accuracy and procedural safety. Innovations in robotics and AI-driven software platforms are also enabling more predictable outcomes and expanding the complexity of tumors that can be treated percutaneously. Furthermore, developments in electrode design, cooling mechanisms, and multiprobe synchronization are supporting better tumor coverage, reduced recurrence rates, and the ability to treat multiple lesions simultaneously.

Research is also progressing in non-thermal ablation modalities, such as irreversible electroporation (IRE), which uses electrical pulses to permeabilize cell membranes and induce apoptosis without significant heating—making it suitable for tumors near critical structures like bile ducts and blood vessels. These expanding options are broadening the scope and safety of interventional oncology treatments.

Which Patient Populations and Clinical Settings Are Driving Adoption of Ablative Therapies?

Patients with unresectable or medically inoperable tumors are the primary candidates for interventional oncology ablation. The approach is commonly adopted in hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer, where it offers curative potential in early-stage disease and palliative benefits in advanced cases. Lung and kidney tumors are also frequently managed using percutaneous ablation, especially in patients with comorbidities that preclude surgery.

Oncology centers, tertiary hospitals, and outpatient interventional radiology clinics are major settings for ablation procedures. Growing integration of interventional oncology into multidisciplinary cancer care teams is facilitating broader adoption, where ablation complements surgery, systemic therapy, and radiotherapy. In many healthcare systems, increasing access to diagnostic imaging, minimally invasive infrastructure, and specialist training is enhancing procedural uptake. Moreover, patient demand for personalized, low-trauma treatment options is shifting preferences toward ablation over more invasive interventions.

The Growth in the Interventional Oncology Ablation Market Is Driven by Several Factors…

The growth in the interventional oncology ablation market is driven by several factors including rising global cancer incidence, increasing demand for minimally invasive therapies, and technological innovation in image-guided intervention. As oncology care evolves toward personalized, targeted, and less disruptive treatment paradigms, ablation offers a compelling solution for patients who are not candidates for traditional surgery or wish to avoid systemic toxicity. Advances in thermal and non-thermal ablation technologies are expanding the range of treatable tumors and improving outcomes in both curative and palliative settings.

Healthcare systems are increasingly recognizing the cost-effectiveness of ablation, particularly in outpatient and day-care settings, where reduced hospitalization and faster recovery translate into significant economic savings. Reimbursement improvements, regulatory approvals of new devices, and the inclusion of ablation in major treatment guidelines are further accelerating market adoption. Additionally, the increasing use of ablation as part of combination therapy with immuno-oncology agents is opening new frontiers in cancer treatment. As interventional oncology becomes more integrated into mainstream oncology pathways, tumor ablation is poised for robust global expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Interventional Oncology Ablation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation); Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Other Indications); End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AngioDynamics
• Boston Scientific Corporation
• CASCINATION AG
• Cook Medical
• DFINE, Inc.
• EDAP TMS S.A.
• GE HealthCare
• HealthTronics
• Intuitive Surgical
• Medtronic plc
• Merit Medical Systems, Inc.
• Profound Medical
• STARmed Co., Ltd.
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation
• Varian Medical Systems (now part of Siemens Healthineers)
• Visionect d.o.o.
• ZAP Surgical Systems, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.